Clinical Trials Logo

Clinical Trial Summary

Purpose: To determine if inhaled hypertonic saline (HS) accelerates airway mucociliary clearance (MCC) in well-controlled moderate to severe asthmatics.


Clinical Trial Description

Participants: Non-smoking adults with well controlled moderate to severe asthma Procedures (methods): After undergoing a general health screen, participants will undergo a lung transmission scan to create an image of the lungs. In subsequent visits, participants will inhale nebulized radiolabeled aerosol and sit in front of a gamma camera for 2 hours to measure clearance of radiolabeled particles from the lungs (procedure called gamma scintigraphy), which will be used to calculate baseline MCC. Spirometry will be performed before and at regular intervals after HS to assess for clinically significant reductions in lung function. Vital signs and symptom questionnaires will be administered as well. If participants are deemed tolerant to HS (i.e., no clinically significant deterioration in lung function, vital signs, or symptom questionnaire scores), participants will move forward with study visits. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03556683
Study type Interventional
Source University of North Carolina, Chapel Hill
Contact Bethany Bradford
Phone 9199662879
Email bgbradfo@email.unc.edu
Status Recruiting
Phase N/A
Start date October 1, 2018
Completion date November 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05774340 - A Study of CM326 in Subjects With Moderate to Severe Asthma Phase 2
Recruiting NCT05851443 - A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma Phase 2
Recruiting NCT06385236 - Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping Phase 4
Completed NCT05062759 - Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma Phase 3
Completed NCT04307173 - Study of Multiple Ascending Dose of KBL693 in Healthy Participants Phase 1
Recruiting NCT05761028 - A Study of CM310 in Subjects With Moderate to Severe Asthma Phase 2/Phase 3